曾木圣

姓名：曾木圣

职称： 博士、研究员、博士生导师、华南肿瘤防治全国重点实验室PI

职务： 中心副主任、副院长

专长： 病毒致癌机制与干预

曾木圣教授现任中山大学肿瘤防治中心副主任/副院长, “国际EB病毒及相关疾病研究协会”主席、中国抗癌协会肿瘤微环境专业委员会主委、广东省肿瘤免疫与疫苗工程技术研究中心主任，广东省细胞生物学会第四届理事会理事长及2024 Gordon Research Conference鼻咽癌国际会议主席。入选长江学者特聘教授、“南粤百杰”和第九届国家卫生健康突出贡献中青年专家等。获国家杰出青年科学基金、国家重点研发计划2项及多项国自然重点项目。长期专注于EB病毒致癌机制与靶向干预研究，首次发现EB病毒感染上皮细胞特异性受体，以及B细胞和上皮细胞通用受体，提出多受体序贯协同介导EB病毒跨细胞感染新理论，建立EB病毒创新疫苗体系，研发出多个候选疫苗并成功转让给国内龙头企业。以通讯或共同通讯作者在Nature, Nat Microbiol(2), Cell Host & Microbe, Cell Res，Cancer Cell，Lancet DH，PNAS，J Clin Invest等国际主流期刊发表论文100多篇。以第一完成人分别获国家自然科学二等奖（2023），高等学校科学研究优秀成果奖（2022）、广东省自然科学奖（2018和2023）和中国抗癌协会科技奖一等奖。H指数73（Google）。

学科：1）肿瘤学 2）生物化学与分子生物学 3）医学微生物学

专业特长：病毒致癌机制与干预

研究方向：

1. 肿瘤病毒感染、致癌机制与免疫调控

2. 肿瘤疫苗和抗体

3. 分子影像及靶向治疗

联系电话：020-87343191;（Fax）：020-87342021，Email: zengmsh@sysucc.org.cn

通讯地址：广州市东风东路651号　中山大学肿瘤防治中心实验研究部　  邮编:510060

教育经历

1988年毕业于江西医学院抚州分院（现南昌大学抚州医学院） 

1994年毕业于中山大学（原中山医科大学），获肿瘤学硕士学位

1998年毕业于中山大学（原中山医科大学），获微生物学博士学位

留学经历

1999-2000年美国田纳西州立大学生物系（Tennessee State University）博士后，从事维甲酸在细胞发育及分化中作用的研究

2000-2003年美国波士顿塔夫茨大学—新英格兰医学中心(Tufts University-New England Medical Center)肿瘤生物学实验室从事HPV致癌机制研究

工作经历

1988年8月至1991年8月，江西德胜关垦殖场职工医院住院医师

1994年7月至1996年，中山医科大学肿瘤防治中心/研究实习员

1996年12月至2003年，中山医科大学肿瘤防治中心/助理研究员

1999年11月至2000年11月，田纳西州立大学/博士后研究助理

2000年11月至2003年，塔夫斯-新英格兰医学中心/博士后研究助理

2003年12月至2006年，中山大学肿瘤防治中心/副研究员

2006年12月至今，中山大学肿瘤防治中心/研究员

科研成就

EB病毒（EBV）是第一个被发现的人类肿瘤病毒，是传染性单核细胞增多症病因，每年引起25万多新发肿瘤患者，包括鼻咽癌、部分胃癌及多种淋巴瘤等，此外，还引起多发性硬化症、系统性红斑狼疮等自身免疫性疾病，每年新发病例超千万。因而，EBV疫苗研发具有巨大的科学价值和社会意义，但在免疫原优化、有效性评估和技术平台等方面面临诸多科技瓶颈，以至于1964年发现EBV至今，国际上仍无疫苗上市。

曾木圣教授长期致力于 EBV感染与致病机制研究。针对 EBV 感染与致病机制长期不清、缺乏有效防控手段的困境，开展系列研究，发现了 EBV 感染关键受体，揭示了 EBV 致癌分子机制，研发了 EBV 新型候选疫苗并成功转让给国内疫苗龙头企业。在 EBV 病毒生物学和致病机制研究中做出系统创新性工作，是领域重要引领者，是现任“国际 EBV 与相关疾病研究协会（创立于 1987 年）”主席。

一、发现了 EBV 感染细胞关键受体，提出了多受体协同感染新理论，为防感染疫苗研发奠定理论基础

EBV 通过在上皮细胞与 B淋巴细胞两类细胞之间的交互感染，完成“感染-潜伏-复制-传播”的生命周期，并诱发 EBV 各类相关疾病。受体是病毒突破细胞屏障的第一道分子关卡，是预防病毒感染的关键靶标。但半世纪来，EBV 在上皮细胞和 B淋巴细胞之间交互感染的机制一直不清，EBV 感染上皮细胞的受体一直未被发现，感染 B 淋巴细胞的机制也未充分阐明，严重制约疫苗和抗病毒药物研发。

首创 EBV 高效感染模型并发现了上皮细胞感染关键受体：EBV 体外感染上皮细胞效率低，极大限制了 EBV 感染受体的鉴定和感染机制的研究。他攻克了这项“卡脖子”难题，首创可提升 EBV 感染效率近 40 倍的永生化上皮细胞类器官模型；经系统筛选，首次鉴定了 EBV 感染上皮细胞的多个特异性关键受体/共受体，其中 NMHC-IIA 介导黏附，NRP1 激活巨胞饮促进内化，EphA2 和 DSC2 触发与宿主细胞膜融合；揭示了它们序贯、协同实现 EBV 感染的深层机制，填补了半世纪来 EBV 感染上皮细胞受体不明、机制不清的研究空白，为病毒侵入抑制剂和防感染疫苗研发提供创新理论支持和全新靶点。

EBV 只感染人和国家一级保护动物狨猴，制约了基于动物模型的感染机制与干预研究。他发现桥粒蛋白 DSC2 是宿主选择性受体，通过外源转染人源 hDSC2 基因，可使啮齿类动物细胞获得对 EBV 易感性，为建立 EBV 感染和致病动物模型以及发展干预手段提供科学依据。

发现了 EBV 感染细胞通用受体 R9AP，提出了以 R9AP 为核心的多受体协同感染新理论：长期以来，一直认为 EBV 感染上皮细胞与 B 淋巴细胞完全依赖各自特异性受体，缺乏共同阻断靶标。应用前述创新感染模型，他鉴定出 EBV 感染上皮细胞与 B 淋巴细胞的通用受体 R9AP，它与病毒糖蛋白 gHgL 直接作用，介导膜融合，在 EBV 感染两类细胞过程中均不可或缺，颠覆了传统观点。

针对 EBV 在上皮细胞和 B 淋巴细胞间交互感染机制不清的问题，他发现 B 淋巴细胞来源的 EBV，其糖蛋白 gHgL 直接结合宿主受体 R9AP 和 EphA2，介导上皮细胞感染；另一方面，上皮细胞来源的 EBV 富含 gHgLgp42 三聚体，其 gp42 遮蔽了 gHgL 上 R9AP结合位点，需先结合 gp42 受体 HLA-II，释放 R9AP 结合位点后，最终完成 B 淋巴细胞感染；但正常上皮细胞因缺乏 HLA-II，对上皮细胞来源的 EBV 不易感。解答了 EBV如何交互感染两类靶细胞的长期未解之谜，提出了以通用受体 R9AP 为核心，协同特异性受体实现 EBV 感染的系统理论框架。

传统认为胞外段为极短 C 端的 R9AP，为何能作为 EBV 受体？他发现，R9AP 较长 N端亦可定位于细胞膜外，并通过与 EBV 糖蛋白 gHgL 互作介导感染。这突破了 R9AP 的 N 端仅定位于胞内、发挥信号传导作用及跨膜蛋白生理状态下只有单向定位的传统认知。通过 R9AP 衍生肽、单克隆抗体等靶向阻断 EBV 与 R9AP 互作，可切断 EBV“感染-潜伏-复制-传播”的链条，为新型干预策略设计提供了理论支撑和关键靶标。该成果以最后通讯作者发表在 Nature。

以上这些关键受体的发现填补了国际 EBV 受体研究空白，推动 EBV 防控研究跃升至 机 制 清 晰 、 靶 点 明 确 的 新 阶 段 ， 被 《 Fields Virology 》 第 七 版 、《 Human Herpesviruses》等国际权威教材和专著收录，并被 Cell，Science 等国际著名期刊正面引用；多次应邀在国际 EBV 会议做大会报告；EBV 感染上皮细胞受体的重要发现也作为核心成果，获得国家自然科学奖二等奖。

• 发现了 EBV gp42 抗体水平降低、受体 HLA-II 异常表达是 EBV 鼻咽感染和致癌的关键事件，为防癌新策略提供科学依据

EBV 相关鼻咽癌在我国最高发，其防治是我国人民健康重大需求。然而，EBV 何时、如何感染局部鼻咽黏膜，如何导致鼻咽癌发生一直是未解之谜，极大地限制了高危人群识别和早期干预策略建立。

为攻克该难题，曾教授与合作者在高发区开展长达 10 年随访的多中心 7.5 万参与者前瞻性队列研究，发现了 EBV 糖蛋白抗体 gp42-IgG 水平下降，鼻咽癌发病风险增加近 20 倍。gp42-IgG 作为首个被鉴定的鼻咽黏膜癌变的保护性抗体，为高危人群早筛提供了关键标志物。

gp42-IgG 如何发挥保护性作用？曾教授首次发现鼻咽癌前病变黏膜的上皮细胞异常表达 B 淋巴细胞感染受体 HLA-II，突破了 EBV 在上皮细胞与 B 淋巴细胞间交互感染限制；gp42-IgG 保护性抗体水平降低，使癌前病变黏膜对富含 gHgLgp42 上皮细胞来源的EBV 高度易感。随后，EBV 感染通过诱导上皮-间质转化、上皮-免疫双表型等细胞可塑性机制，导致鼻咽癌变、肿瘤转移与治疗抵抗。

国际同行评述认为“首次明确鼻咽黏膜保护性抗体，并解答了 EBV 致癌的关键时间节点与分子事件，为设计新一代以 gp42 为靶点的防致癌疫苗奠定创新理论基础”；曾木圣教授也受邀就 gp42-IgG 作为鼻咽癌高危人群标志物及以 gp42 为靶点在防治鼻咽癌的应用前景撰写专家观点（Mol Ther, 2025），此外，上皮-免疫双表型特殊亚群的发现也被认为是“EBV 及鼻咽癌相关研究的里程碑式进展”。

三、研发了预防 EBV 感染和致癌的新型候选疫苗

 EBV 感染相关疾病全球每年新发病例超千万，疾病负担沉重，严重危害健康。对于未感染 EBV 人群，疫苗可通过预防病毒感染，从病因源头防止各类相关疾病发生；对已感染 EBV 的高风险人群，疫苗则可通过阻断致癌过程或增强抗肿瘤免疫，降低肿瘤发生风险或提升治疗效果。然而，EBV 疫苗研发至今近半个世纪，仍未有上市。

针对 EBV 防感染疫苗研发的瓶颈，曾教授在上述关键受体及感染机制的创新发现基础上，进一步解析了 EBV 衣壳高分辨率结构（封面论文），阐明了病毒与受体互作机制（Cell Rep, 2025），鉴定了多株阻断病毒与受体互作、靶向 EBV 糖蛋白 gHgL，gp42 和 gB 的高效中和抗体（Cell Rep Med, 2024；Nat Commun, 2021）。继而建立了自组装纳米颗粒创新疫苗平台（ACS Nano, 2021, 高被引），并打破用 EBV 糖蛋白gp350 为核心疫苗靶标以预防 B 淋巴细胞感染的传统策略，研发了能同时提供对 B 淋巴细胞和上皮细胞保护的 gHgL 和 gB 新型候选疫苗，可更加有效预防 EBV 感染（封面论文）。相关成果转让给疫苗龙头企业，目前正开展临床前工艺及药效学研究。

针对鼻咽黏膜癌前病变的感染机制，曾教授提出并研发了以 gp42 为核心疫苗靶标的防癌候选疫苗，用以阻断 EBV 感染癌前病变黏膜，从“预防初次感染”进一步拓展到“防止激活、再感染和致癌”，同时，研发了靶向 EBV 抗原的肿瘤治疗性候选疫苗（J Virol, 2022；Adv Sci, 2023），并与疫苗创新企业合作，目前完成临床前药效、毒理以及产品质量检测，正申报新药临床试验研究。

综上，曾教授发现了 EBV 感染关键受体、阐明了 EBV 致癌分子机制，提出了 EBV 感染和致癌的理论框架，为从源头阻断 EBV 感染和预防肿瘤发生提供了理论基础与实施策略，并指导了 EBV 体系化新型疫苗的研发。其研究成果代表我国科研力量在服务人类重大感染性疾病防控中的重大突破。

科研项目

1. 国家自然科学基金专项项目，32441094 , EBV相关儿童SLE的临床特征、发病机制与干预，2025-2027, 297万
2. 国家自然科学基金联合基金项目，U24A20743 , EB病毒糖蛋白宿主互作机制及候选新型疫苗研究，2025-2028，260万
3. 国家重点研发计划项目负责人，2022YFC3400900，中国高发肿瘤单细胞多组学整合分析及转化研究，2022-2027，1920万
4. 国家自然科学基金重点项目，82030046，基于pre-gB结构及其受体互作的EB病毒新型疫苗设计，2021-2025，297万
5. 国家自然科学基金重点项目，81830090，鼻咽癌中YTHDF1复合体降解病毒m6A修饰RNA调控EBV感染状态及肿瘤进展，2019-2023，295万
6. 国家重点研发计划项目负责人，2017YFA0505600，“基于基因组不稳定性的新型蛋白质机器在肿瘤发生发展中的作用、机制及干预”，2017-2022，1883万
7. 国家重点研发计划子课题参与人“疱疹病毒感染与致病过程中蛋白质机器的功能机制”2016-2021
8. 国家自然科学基金国际(地区)合作与交流项目，81520108022，EB病毒进入鼻咽上皮细胞受体鉴定及感染机制，2016-2020
9. 国家自然科学基金重大研究计划，91440106，RNA结合蛋白RBM24调控miR-25-3p及lncRNA MALAT1抑制鼻咽癌的机制，2015-2017
10. 国家自然科学基金重点项目，81230045，融合基因AARS-MADx诱导基因组不稳定性及参与鼻咽癌发生的机制，2013-2017
11. “973”课题：“致瘤病毒感染和致癌机制”，2011-2017
12. 国家自然科学基金杰出青年基金，81025014，头颈肿瘤，2011-2014
13. 国家自然科学基金重点项目，30630068，鼻咽癌早期诊断的基础研究，2007-2010
14. “863”计划课题（2007AA02Z477）鼻咽癌早期诊断新方法研究，2007-2010

科技奖励

1. 2023年国家自然科学奖二等奖，《EB病毒致癌分子机制与靶向干预》，曾木圣、刘强、贝锦新、徐淼、白凡
2. 2023年广东省自然科学奖一等奖，《高危EB病毒亚型鉴定、致癌机制与靶向干预》，曾木圣、徐淼、白凡、冯琳、张华、向橦、钟茜、李燕、夏天亮
3. 2022年高等学校科学研究优秀成果奖一等奖，《鼻咽癌EBV高危亚型的鉴定、感染及其致癌机制》，曾木圣、徐淼、冯琳、张华、曾益新、向橦、钟茜
4. 2018年广东省自然科学奖一等奖，《EBV相关鼻咽癌病因、发病机制及分子标志的研究》，曾木圣、曾益新、宋立兵、谢丹、麦海强、钱朝南、曹素梅、薛文琼
5. 2019年中国抗癌协会科技奖一等奖，《EBV感染、致癌机制及其分子标志》，曾木圣、宋立兵、谢丹、麦海强、曾益新、钱朝南、曹素梅、薛文琼

代表性论文

1. R9AP is a common receptor for EBV infection in epithelial cells and B cells. Yan Li ^#, Hua Zhang ^#, Cong Sun ^#, Xiao-Dong Dong ^#, Chu Xie, Yuan-Tao Liu, Ruo-Bin Lin, Xiang-Wei Kong, Zhu-Long Hu, Xiao-Yan Ma, Dan-Ling Dai, Qian-Ying Zhu, Yu-Chun Li, Ying Li, Shang-Xin Liu, Li Yuan, Peng-Hui Zhou, Song Gao, Ya-Ping Tang, Jin-Ying Yang, Ping Han, Andrew T McGuire, Bo Zhao, Jin-Xin Bei, Erle Robertson, Yi-Xin Zeng, Qian Zhong*, Mu-Sheng Zeng*. Nature. 2025 Aug;644(8075):205-213. doi: 10.1038/s41586-025-09166-w. Epub 2025 Jun 18.
2. Desmocollin 2 is a dominant entry receptor for Epstein-Barr virus infection of epithelial cells. Hua Zhang ^#, Yu-Chun Li ^#, De Pang ^#, Chu Xie ^#, Ting Zhang, Ying Li, Yan Li, Zi-Ying Jiang, Guo-Long Bu, Meng-Meng Liu, Ying-Rou Chen, Han-Xiao Fei, Ruo-Bin Lin, Pei-Huang Wu, Wen-Ting Du, Ge-Xin Zhao, Yi-Ling Luo, Ping Han, Qian Zhong*, Cong Sun*, Mu-Sheng Zeng*. Nat Microbiol. 2025 Jul 25. doi: 10.1038/s41564-025-02067-8.
3. A large-scale population-based study reveals that gp42-IgG antibody is protective against Epstein-Barr virus-associated nasopharyngeal carcinoma. Xiang-Wei Kong^#, Guo-Long Bu^#, Hua Chen^#, Yu-Hua Huang^#, Zhiwei Liu, Yin-Feng Kang, Yan-Cheng Li, Xia Yu, Biao-Hua Wu, Zi-Qian Li, Xin-Chun Chen, Shang-Hang Xie, Dong-Feng Lin, Tong Li, Shu-Mei Yan, Run-Kun Han, Nan Huang, Qian-Yu Wang, Yan Li, Ao Zhang, Qian Zhong, Xiao-Ming Huang, Weimin Ye, Ming-Fang Ji*, Yong-Lin Cai*, Su-Mei Cao*, Mu-Sheng Zeng*. J Clin Invest. 2024 Nov 26:e180216. doi: 10.1172/JCI180216.
4. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cong Sun^#, Yin-Feng Kang^#, Xin-Yan Fang^#, Yi-Na Liu^#, Guo-Long Bu, Ao-Jie Wang, Yan Li, Qian-Ying Zhu, Hua Zhang, Chu Xie, Xiang-Wei Kong, Yong-Jian Peng, Wen-Jie Lin, Ling Zhou, Xin-Chun Chen, Zheng-Zhou Lu, Hui-Qin Xu, Dong-Chun Hong, Xiao Zhang, Ling Zhong, Guo-Kai Feng, Yi-Xin Zeng, Miao Xu, Qian Zhong*, Zheng Liu*, Mu-Sheng Zeng*. Cell Host Microbe. 2023 Nov 8;31(11):1882-1897.e10. doi: 10.1016/j.chom.2023.09.011.
5. Neuropilin 1 is an entry receptor for KSHV infection of mesenchymal stem cell through TGFBR1/2-mediated macropinocytosis. Zheng-Zhou Lu^#, Cong Sun^#, Xiaolin Zhang, Yingying Peng, Yan Wang, Yan Zeng, Nannan Zhu, Yan Yuan*, Mu-Sheng Zeng*. Sci Adv. 2023 May 24;9(21):eadg1778. doi: 10.1126/sciadv.adg1778. Epub 2023 May 24.
6. Single-cell transcriptomic analysis defines the interplay between tumor cells,viral infection, and the microenvironment in nasopharyngeal carcinoma.Shanzhao Jin^#, Ruoyan Li^#, Ming-Yuan Chen^#, Chao Yu^#, Lin-Quan Tang^#, Yan-Min Liu, Jiang-Ping Li, Yi-Na Liu, Yi-Ling Luo, Yifan Zhao, Yu Zhang, Tian-Liang Xia, Shang-Xin Liu, Qi Liu, Guan-Nan Wang, Rui You, Jing-Yun Peng, Jiang Li, Feng Han, Jianwei Wang, Qiu-Yan Chen, Li Zhang, Hai-Qiang Mai, Benjamin E Gewurz, Bo Zhao, Lawrence S Young, Qian Zhong*, Fan Bai*, Mu-Sheng Zeng*. Cell Res. 2020 Nov;30(11):950-965. doi: 10.1038/s41422-020-00402-8. Epub 2020 Sep 8.
7. Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. Hua Zhang^#, Yan Li^#, Hong-Bo Wang^#, Ao Zhang, Mei-Ling Chen, Zhi-Xin Fang, Xiao-Dong Dong, Shi-Bing Li, Yong Du, Dan Xiong, Jiang-Yi He, Man-Zhi Li, Yan-Min Liu, Ai-Jun Zhou, Qian Zhong, Yi-Xin Zeng, Elliott Kieff, Zhiqiang Zhang, Benjamin E. Gewurz, Bo Zhao* & Mu-Sheng Zeng*. Nat Microbiol. 2018 Feb;3(2):1-8. doi: 10.1038/s41564-017-0080-8. Epub 2018 Jan 1.
8. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Hong-Bo Wang^#, Hua Zhang^#, Jing-Ping Zhang, Yan Li, Bo Zhao, Guo-Kai Feng, Yong Du, Dan Xiong, Qian Zhong, Wan-Li Liu, Huamao Du, Man-Zhi Li, Wen-Lin Huang, Sai Wah Tsao, Lindsey Hutt-Fletcher, Yi-Xin Zeng, Elliott Kieff, Mu-Sheng Zeng*. Nat Commun. 2015 Feb 11:6:6240. doi: 10.1038/ncomms7240.
9. Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Dan Xiong^#, Yong Du^#, Hong-Bo Wang^#, Bo Zhao, Hua Zhang, Yan Li, Li-Juan Hu, Jing-Yan Cao, Qian Zhong, Wan-Li Liu, Man-Zhi Li, Xiao-Feng Zhu, Sai Wah Tsao, Lindsey M Hutt-Fletcher, Erwei Song, Yi-Xin Zeng, Elliott Kieff*, Mu-Sheng Zeng*.  Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11036-41. doi: 10.1073/pnas.1513359112. Epub 2015 Aug 19.
10. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. Li-Bing Song^#, Jun Li^#, Wen-Ting Liao^#, Yan Feng, Chun-Ping Yu, Li-Juan Hu, Qing-Li Kong, Li-Hua Xu, Xing Zhang, Wan-Li Liu, Man-Zhi Li, Ling Zhang, Tie-Bang Kang, Li-Wu Fu, Wen-Lin Huang, Yun-Fei Xia, Sai Wah Tsao, Mengfeng Li, Vimla Band, Hamid Band, Qing-Hua Shi, Yi-Xin Zeng, Mu-Sheng Zeng*. J Clin Invest. 2009 Dec;119(12):3626-36. doi: 10.1172/JCI39374. Epub 2009 Nov 2.

其他发表论文

1. The PLEKHA1-TACC2 fusion gene drives tumorigenesis via vascular mimicry formation in esophageal squamous-cell carcinoma. Ting Yang^#, Zhi-Rui Lin^#, Tian-Liang Xia^#, Shang-Xin Liu^#, Bo-Yu Yuan, Yi-Ling Luo, Wen-Ting Du, Chao-Bo Lei, Yong-Zhan Nie, Mu-Sheng Zeng*, Qian Zhong*. Cell Death Differ. Published online July 5, 2025. doi:10.1038/s41418-025-01536-1.
2. Inactivation of TACC2 epigenetically represses CDKN1A and confers sensitivity to CDK inhibitors. Zhi-Rui Lin^#, Tian-Liang Xia^#, Meng-Yao Wang^#, Lan-Jun Zhang, Yan-Min Liu, Bo-Yu Yuan, Ai-Jun Zhou, Li Yuan, Jian Zheng, Jin-Xin Bei, Dong-Xin Lin, Mu-Sheng Zeng*, Qian Zhong*. Med. 2025;6(5):100568. doi:10.1016/j.medj.2024.12.002.
3. Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Shang-Xin Liu^#,  Tao-Wei Wu^#, Dong-Hua Luo, Le-Le Zhang, Lu Zhou, Yi-Ling Luo, Wen-Ting Du, Ting-Ting Huang, Sizun Jiang, Zhe Zhang*, Ping Han*, Mu-Sheng Zeng*, Qian Zhong*. Cell Rep Med. 2025;6(7):102200. doi:10.1016/j.xcrm.2025.102200.
4. OASL enhances mRNA translation and reprograms lipid metabolism to promote cancer progression. Shi-Bing Li^#, Li Yuan^#, Qian-Ying Zhu^#, Gong Zhang, Yuan-Tao Liu,  Ming-Hui Gao, Fei Han, Zhi-Rui Lin, Hua Zhang, Lin-Quan Tang, Li Sun, Qing-Yu He, Er-Wei Song, Lawrence S Young, Yu-Chun Li, Hai-Qiang Mai, Mu-Sheng Zeng*, Qian Zhong*. Cell Rep. 2025;44(7):115901. doi:10.1016/j.celrep.2025.115901.
5. Targeting EBV gp42 for nasopharyngeal carcinoma prevention. Cong Sun^#, Le-Le Zhang, Mu-Sheng Zeng*. Mol Ther. 2025;33(7):2987-2989. doi:10.1016/j.ymthe.2025.06.005.
6. mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust AntiTumor Immunityin Mice. Ge-Xin Zhao, Guo-Long Bu, Gang-Feng Liu, Xiang-Wei Kong, Cong Sun, Zi-Qian Li, Dan-Ling Dai, Hai-Xia Sun, Yin-Feng Kang, Guo-Kai Feng*, Qian Zhong*, Mu-Sheng Zeng*. Adv Sci (Weinh). 2023 Dec;10(35):e2302116. doi: 10.1002/advs.202302116. Epub 2023 Oct 27.
7. Highly sensitive detection platform-based diagnosis of oesophageal squamous cell carcinoma in China: a multicentre, case-control, diagnostic study. Yu Wang^#, Shan Xing^#, Yi-Wei Xu^#, Qing-Xia Xu^#, Ming-Fang Ji^#, Yu-Hui Peng^#, Ya-Xian Wu, Meng Wu, Ning Xue, Biao Zhang, Shang-Hang Xie, Rui-Dan Zhu, Xin-Yuan Ou, Qi Huang, Bo-Yu Tian, Hui-Lan Li, Yu Jiang, Xiao-Bin Yao, Jian-Pei Li, Li Ling, Su-Mei Cao*, Qian Zhong*, Wan-Li Liu*, Mu-Sheng Zeng*. Lancet Digit Health. 2024 Oct;6(10):e705-e717. doi: 10.1016/S2589-7500(24)00153-5.
8. Research landmarks on the 60th anniversary of Epstein-Barr virus. Lan-Yi Zhong^#, Chu Xie^#, Le-Le Zhang^#, Yan-Lin Yang^#, Yuan-Tao Liu^# Ge-Xin Zhao, Guo-Long Bu, Xian-Shu Tian, Zi-Ying Jiang Bo-Yu Yuan, Peng-Lin Li, Pei-Huang Wu, Wei-Hua Jia, Christian Münz, Benjamin E Gewurz, Qian Zhong, Cong Sun, Mu-Sheng Zeng*. Sci China Life Sci. 2025;68(2):354-380. doi:10.1007/s11427-024-2766-0.
9. Structural basis of Epstein-Barr virus gp350 receptor recognition and neutralization. Cong Sun^#, Xin-Yan Fang, Guo-Long Bu, Lan-Yi Zhong, Chu Xie, Ge-Xin Zhao, Sen-Fang Sui, Zheng Liu, Mu-Sheng Zeng*. Cell Rep. 2025;44(1):115168. doi:10.1016/j.celrep.2024.115168.
10. AXIN1 boosts antiviral response through IRF3 stabilization and induced phase separation. Dan-Ling Dai^#, Chu Xie^#, Lan-Yi Zhong^#, Shang-Xin Liu, Le-Le Zhang, Hua Zhang, Xing-Ping Wu, Zhou-Ming Wu, Kexin Kang, Yan Li, Ya-Meng Sun, Tian-Liang Xia, Chen-Song Zhang, Ao Zhang, Ming Shi, Cong Sun, Mei-Ling Chen, Ge-Xin Zhao, Guo-Long Bu, Yuan-Tao Liu, Kui-Yuan Huang, Zheng Zhao, Shu-Xin Li, Xiao-Yong Zhang, Yun-Fei Yuan, Shi-Jun Wen, Lingqiang Zhang, Bin-Kui Li*, Qian Zhong*, Mu-Sheng Zeng*. Signal Transduct Target Ther. 2024 Oct 9;9(1):281. doi: 10.1038/s41392-024-01978-y.
11. Research landmarks on the 60th anniversary of Epstein-Barr virus. Lan-Yi Zhong^#, Chu Xie^#, Le-Le Zhang^#, Yan-Lin Yang^#, Yuan-Tao Liu^#, Ge-Xin Zhao, Guo-Long Bu, Xian-Shu Tian, Zi-Ying Jiang, Bo-Yu Yuan, Peng-Lin Li, Pei-Huang Wu, Wei-Hua Jia, Christian Münz, Benjamin E Gewurz, Qian Zhong, Cong Sun*, Mu-Sheng Zeng*. Sci China Life Sci. 2024 Nov 4. doi: 10.1007/s11427-024-2766-0. Online ahead of print.
12. Prophylactic vaccines against Epstein-Barr virus. Ling Zhong, Qinjian Zhao, Mu-Sheng Zeng, Xiao Zhang*. Lancet. 2024 Aug 31;404(10455):845. doi: 10.1016/S0140-6736(24)01608-8.
13. Primary and Orthotopic Murine Models of Nasopharyngeal Carcinoma Reveal Molecular Mechanisms Underlying its Malignant Progression. Xudong Wan, Yuantao Liu, Yiman Peng, Jian Wang, Shu-mei Yan, Lu Zhang, Wanchun Wu, Lei Zhao, Xuelan Chen, Kexin Ren, Haicheng Long, Yiling Luo, Qin Yan, Lele Zhang, Dengzhi Lei, Pengpeng Liu, Shujun Li, Lihui Liu, Linjie Guo, Jiajia Du, Mengsha Zhang, Siqi Dai, Yi Yang, Hongyu Liu, Nianyong Chen, Jinxin Bei, Lin Feng, Yu Liu*, Mu-sheng Zeng*, Chong Chen*, and Qian Zhong*. Adv Sci (Weinh). 2024 Sep;11(36):e2403161. doi: 10.1002/advs.202403161. Epub 2024 Jul 25.
14. A pan-KRAS degrader for the treatment of KRAS-mutant cancers. Jie Yang^#, Qiao-Li Wang^#, Guan-Nan Wang, Jia-Cong Ye, Zi-Qian Li, Jing-Yun Wang, Zhao-Hui Liang, Shu-Xin Li, Cong Sun, Wen-Ting Liao, Yi-Jun Gao, Jing Wang, Yong Mao, Chunjing Yu, Guo-Kai Feng*, Mu-Sheng Zeng*. Cell Discov. 2024 Jun 28;10(1):70. doi: 10.1038/s41421-024-00699-4.
15. Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection. Ge-Xin Zhao^#, Xin-Yan Fang^#, Guo-Long Bu^#, Shuai-Jia-Bin Chen, Cong Sun, Ting Li, Chu Xie, Yu Wang, Shu-Xin Li, Ning Meng, Guo-Kai Feng, Qian Zhong, Xiang-Wei Kong*, Zheng Liu*, Mu-Sheng Zeng*. Cell Rep Med. 2024 May 21;5(5):101573. doi: 10.1016/j.xcrm.2024.101573.
16. Evaluation of serum Epstein-Barr virus envelope glycoproteins antibodies and their association with systemic autoimmune diseases. Hui-Lan Li^#, Lan-Yi Zhong^#, Yin-Feng Kang, Yan-Lan Yang, Liang Shi, Ai-Xia Zhai, Chao Wu, Mu-Sheng Zeng*, Qian-Ying Zhu*. J Med Virol. 2024 Apr;96(4):e29595. doi: 10.1002/jmv.29595.
17. Navigating Epstein-Barr virus autoimmunity: role of NK cells and T cells in multiple sclerosis. Chu Xie, Cong Sun*, Mu-Sheng Zeng*. Signal Transduct Target Ther. 2024 Feb 29;9(1):48. doi: 10.1038/s41392-024-01774-8.
18. Enhancing immune defense against COVID-19: Alveolar delivery of mucosal vaccines. Pei-Huang Wu^#, Dong-Chun Hong^#, Chu Xie, Mu-Sheng Zeng*, Cong Sun*. Sci Bull (Beijing). 2024 Dec 15;69(23):3637-3639. doi: 10.1016/j.scib.2024.07.032. Epub 2024 Jul 19.
19. Elucidation of the neutralizing antibody evasion of emergent SARS-CoV-2 Omicron sub-lineages using structural analysis. Cong Sun^#, Yuan-Tao Liu^#, Yin-Feng Kang, Chu Xie, Shu-Xin Li, Yu-Tong Lu, Mu-Sheng Zeng*. Sci China Life Sci. 2023 Dec;66(12):2935-2938. doi: 10.1007/s11427-023-2393-3. Epub 2023 Sep 1.
20. Anti-EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy. Chu Xie, Lan-Yi Zhong, Guo-Long Bu, Ge-Xin Zhao, Bo-Yu Yuan, Yuan-Tao Liu, Cong Sun*, Mu-Sheng Zeng*. J Med Virol. 2023 May;95(5):e28793. doi: 10.1002/jmv.28793.
21. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Cong Sun, Chu Xie, Guo-Long Bu, Lan-Yi Zhong & Mu-Sheng Zeng*. Signal Transduct Target Ther. 2022 Jun 28;7(1):202. doi: 10.1038/s41392-022-01039-2.
22. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Yin-Feng Kang^#, Cong Sun^#, Jing Sun ^#, Chu Xie, Zhen Zhuang, Hui-Qin Xu, Zheng Liu, Yi-Hao Liu, Sui Peng, Run-Yu Yuan*, Jin-Cun Zhao*, Mu-Sheng Zeng*. Nat Commun. 2022 May 13;13(1):2674. doi: 10.1038/s41467-022-30222-w.
23. Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines. Cong Sun^#, Run-Yu Yuan^#, Chu Xie^#, Jiu-Feng Sun, Xin-Yan Fang, Yi-Sha Hu, Xiao-Hui Yu, Zheng Liu, Mu-Sheng Zeng*, Yin-Feng Kang*. J Virol. 2022 Jul 13;96(13):e0038322. doi: 10.1128/jvi.00383-22. Epub 2022 Jun 14.
24. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses. Xiang-Wei Kong^#, Xiao Zhang^#, Guo-Long Bu^#, Hui-Qin Xu, Yin-Feng Kang, Cong Sun, Qian-Ying Zhu, Run-Bo Ma, Zheng Liu, Yi-Xin Zeng, Mu-Sheng Zeng*, Zhu-Long Hu*. J Virol. 2022 May 11;96(9):e0033622. doi: 10.1128/jvi.00336-22. Epub 2022 Apr 11.
25. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Cong Sun ^#, Yin-Feng Kang ^#, Yuan-Tao Liu, Xiang-Wei Kong, Hui-Qin Xu, Dan Xiong, Chu Xie, Yi-Hao Liu, Sui Peng, Guo-Kai Feng*, Zheng Liu*, Mu-Sheng Zeng*. Signal Transduct Target Ther. 2022 Feb 8;7(1):42. doi: 10.1038/s41392-022-00910-6.
26. The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development. Cong Sun, Xin-Chun Chen, Yin-Feng Kang, Mu-Sheng Zeng*. Front Immunol. 2021 Jun 8:12:677027. doi: 10.3389/fimmu.2021.677027.  eCollection 2021.
27. PD-1+CXCR5-CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. Jiang-Ping Li, Chang-You Wu, Ming-Yuan Chen, Shang-Xin Liu, Shu-Mei Yan, Yin-Feng Kang, Cong Sun, Jennifer R Grandis, Mu-Sheng Zeng*, Qian Zhong*. J Immunother Cancer. 2021 Jul;9(7):e002101. doi: 10.1136/jitc-2020-002101 .
28. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. Qian-Ying Zhu ^#, Sisi Shan ^#, Jinfang Yu ^#, Si-Ying Peng, Cong Sun, Yanan Zuo, Lan-Yi Zhong, Shu-Mei Yan, Xiao Zhang, Ziqing Yang, Yong-Jian Peng, Xuanling Shi, Su-Mei Cao, Xinquan Wang*, Mu-Sheng Zeng*, Linqi Zhang*. Nat Commun. 2021 Nov 16;12(1):6624. doi: 10.1038/s41467-021-26912-6.
29. EBV latent membrane proteins promote hybrid epithelial-mesenchymal and extreme mesenchymal states of nasopharyngeal carcinoma cells for tumorigenicity. Nannan Zhu, Xiaoting Xu, Yan Wang, Mu-Sheng Zeng*, Yan Yuan*. PLoS Pathog. 2021 Aug 18;17(8):e1009873. doi: 10.1371/journal.ppat.1009873.  eCollection 2021 Aug.
30. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. Yin-Feng Kang^#, Cong Sun^#, Zhen Zhuang^#, Run-Yu Yuan^#, Qingbing Zheng, Jiang-Ping Li, Ping-Ping Zhou, Xin-Chun Chen, Zhe Liu, Xiao Zhang, Xiao-Hui Yu, Xiang-Wei Kong, Qian-Ying Zhu, Qian Zhong, Miao Xu, Nan-Shan Zhong, Yi-Xin Zeng, Guo-Kai Feng*, Changwen Ke*, Jin-Cun Zhao*, Mu-Sheng Zeng*. ACS Nano. 2021 Feb 23;15(2):2738-2752. doi: 10.1021/acsnano.0c08379.  Epub 2021 Jan 19.
31. Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection. Yin-Feng Kang^#, Xiao Zhang^#, Xiao-Hui Yu^#, Qingbing Zheng, Zhe Liu, Jiang-Ping Li, Cong Sun, Xiang-Wei Kong, Qian-Ying Zhu, Hai-Wen Chen, Yang Huang, Miao Xu, Qian Zhong, Yi-Xin Zeng*, Mu-Sheng Zeng*. Nano Lett. 2021 Mar 24;21(6):2476-2486. doi: 10.1021/acs.nanolett.0c04687.  Epub 2021 Mar 8.
32. N(6)-methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay.Tian-Liang Xia^#, Xingyang Li^#, Xueping Wang^#, Yun-Jia Zhu, Hua Zhang, Weisheng Cheng, Mei-Ling Chen, Ying Ye, Yan Li, Ao Zhang, Dan-Ling Dai, Qian-Ying Zhu, Li Yuan, Jian Zheng, Huilin Huang, Si-Qi Chen, Zhi-Wen Xiao, Hong-Bo Wang, Gaurab Roy, Qian Zhong, Dongxin Lin, Yi-Xin Zeng, Jinkai Wang, Bo Zhao, Benjamin E Gewurz, Jianjun Chen, Zhixiang Zuo*, Mu-Sheng Zeng*. EMBO Rep. 2021 Apr 7;22(4):e50128. doi: 10.15252/embr.202050128.  Epub 2021 Feb 19.
33. CryoEM structure of the tegumented capsid of Epstein-Barr virus. Zhihai Li ^#, Xiao Zhang ^#, Lili Dong, Jingjing Pang, Miao Xu, Qian Zhong, Mu-Sheng Zeng*, Xuekui Yu*. Cell Res. 2020 Oct;30(10):873-884. doi: 10.1038/s41422-020-0363-0.  Epub 2020 Jul 3.
34. First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Shi Gao^#, Bing Jia^#, Guokai Feng^#, Chengyan Dong, Hui Du, Lin Bai, Qian Zhong , Qingjie Ma*, Musheng Zeng*, Fan Wang*. Signal Transduct Target Ther. . 2020 Aug 11;5(1):147. doi: 10.1038/s41392-020-00266-9.
35. An optimized integrin α6-targeted peptide for positron emission tomography/magnetic resonance imaging of pancreatic cancer and its precancerous lesion. Yan Mei^#, Ying-He Li^#, Xiao-Chun Yang^#, Chao Zhou, Zhi-Jian Li, Xiao-Bin Zheng, Jia-Cong Ye, Cheng Li, Xuan-Hong Zhang, Jian-Min Yuan, Hui-Qiang Huang, Wei Fan, Wei-Guang Zhang*, Mu-Sheng Zeng*, Guo-Kai Feng*. Clin Transl Med. 2020 Aug;10(4):e157. doi: 10.1002/ctm2.157.  
36. EphA2 phosphorylates NLRP3 and inhibits inflammasomes in airway epithelial cells. Ao Zhang ^#, Junji Xing ^#, Tianliang Xia ^#, Hua Zhang, Mingli Fang, Shibing Li, Yong Du, Xian C Li , Zhiqiang Zhang*, Mu-Sheng Zeng*. EMBO Rep. 2020 Jul 3;21(7):e49666. doi: 10.15252/embr.201949666.  Epub 2020 Apr 30.
37. Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling. Shi-Bing Li ^#, Yan-Yan Liu ^#, Li Yuan ^#, Ming-Fang Ji ^#, Ao Zhang, Hui-Yu Li, Lin-Quan Tang, Shuo-Gui Fang, Hua Zhang, Shan Xing, Man-Zhi Li, Qian Zhong, Shao-Jun Lin, Wan-Li Liu, Peng Huang, Yi-Xin Zeng, Yu-Ming Zheng, Zhi-Qiang Ling*, Jian-Hua Sui*, Mu-Sheng Zeng*. EMBO Mol Med. 2020 Sep 7;12(9):e12050. doi: 10.15252/emmm.202012050.  Epub 2020 Jul 12.
38. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Xiao Zhang^#, Bingchun Zhao^#, Mingmei Ding, Shuo Song, Yinfeng Kang, Yang Yu, Miao Xu, Tong Xiang, Ling Gao, Qisheng Feng, Qinjian Zhao, * Mu-Sheng Zeng*, Claude Krummenacher, Yi-Xin Zeng*. Theranostics, 2020 Apr 27;10(13):5704-5718. doi: 10.7150/thno.42494.  eCollection 2020.
39. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Ruidong Xue^#, Lu Chen^#, Chong Zhang^#, Masashi Fujita^#, Ruoyan Li, Shu-Mei Yan, Choon Kiat Ong, Xiwen Liao, Qiang Gao, Shota Sasagawa, Yanmeng Li, Jincheng Wang, Hua Guo, Qi-Tao Huang, Qian Zhong, Jing Tan, Lisha Qi, Wenchen Gong, Zhixian Hong, Meng Li, Jingmin Zhao, Tao Peng, Yinying Lu, Kiat Hon Tony Lim, Arnoud Boot, Atushi Ono, Kazuaki Chayama, Zemin Zhang, Steve George Rozen, Bin Tean Teh, Xin Wei Wang, Hidewaki Nakagawa, Mu-Sheng Zeng*, Fan Bai*, Ning Zhang*. Cancer Cell. 2019 Jun 10;35(6):932-947.e8. doi: 10.1016/j.ccell.2019.04.007. Epub 2019 May 23.
40. Room Temperature Detection of Plasma Epstein-Barr Virus DNA with CRISPR-Cas13. Yetao Wu^#, Shang-Xin Liu^#, Fang Wang, Mu-Sheng Zeng. Clin Chem, 2019 Apr;65(4):591-592. doi: 10.1373/clinchem.2018.299347.  Epub 2019 Feb 12.
41. Genome-wide CRISPR-based gene knockout screens reveal cellular factors and pathways essential for nasopharyngeal carcinoma. Chong Wang, Sizun Jiang, Liangru Ke, Luyao Zhang, Difei Li, Jun Liang, Yohei Narita, Isabella Hou, Chen-Hao Chen, Liangwei Wang, Qian Zhong, Yihong Ling, Xing Lv, Yanqun Xiang, Xiang Guo, Mingxiang Teng, Sai-Wah Tsao, Benjamin E Gewurz, Mu-Sheng Zeng*, Bo Zhao*. J Biol Chem, 2019 Jun 21;294(25):9734-9745. doi: 10.1074/jbc.RA119.008793.  Epub 2019 May 9.
42. Integrin α6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models. Guo-Kai Feng^#, Jia-Cong Ye^#, Wei-Guang Zhang^#, Yan Mei, Chao Zhou, Yi-Tai Xiao, Xin-Ling Li, Wei Fan*, Fan Wang*, Mu-Sheng Zeng*. J Control Release, 2019 Sep 28:310:11-21. doi: 10.1016/j.jconrel.2019.08.003.  Epub 2019 Aug 7.
43. The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Qian Zhong ^#, Zhi-Hua Liu ^#, Zhi-Rui Lin ^#, Ze-Dong Hu, Li Yuan, Yan-Min Liu, Ai-Jun Zhou, Li-Hua Xu, Li-Juan Hu, Zi-Feng Wang, Xin-Yuan Guan, Jia-Jie Hao, Vivian W Y Lui, Ling Guo, Hai-Qiang Mai, Ming-Yuan Chen, Fei Han, Yun-Fei Xia , Jennifer R Grandis, Xing Zhang*, Mu-Sheng Zeng*. Clin Cancer Res. 2018 Feb 1;24(3):659-673. doi: 10.1158/1078-0432.CCR-17-0352.  Epub 2017 Nov 13.
44. Identification of a sodium pump Na(+)/K(+) ATPase α1-targeted peptide for PET imaging of breast cancer. Qian Wang ^#, Shi-Bing Li ^#, Yi-Ying Zhao ^#, Da-Nian Dai, Hui Du, Yan-Zhu Lin, Jia-Cong Ye, Jing Zhao, Wei Xiao, Yan Mei, Yi-Tai Xiao, Shi-Chu Liu, Yan Li, Yun-Fei Xia, Er-Wei Song, Gang-Hua Tang, Wei-Guang Zhang, Zhi-Jian Li, Xiao-Bin Zheng, De-Hai Cao, Man-Zhi Li, Qian Zhong, Zhong-Ping Chen, Chao-Nan Qian, Wei Fan*, Guo-Kai Feng*, Mu-Sheng Zeng*. J Control Release, 2018 Jul 10:281:178-188. doi: 10.1016/j.jconrel.2018.05.019.  Epub 2018 May 17.
45. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. Xi-Xi Chen^#, Qian Zhong^#, Yang Liu^#, Shu-Mei Yan^#, Zhang-Hua Chen^#, Shan-Zhao Jin^#, Tian-Liang Xia, Ruo-Yan Li, Ai-Jun Zhou, Zhe Su, Yu-Hua Huang, Qi-Tao Huang, Li-Yun Huang, Xing Zhang, Yan-Na Zhao, Jin-Ping Yun, Qiu-Liang Wu, Dong-Xin Lin, Fan Bai*, Mu-Sheng Zeng*. Nat Commun, 2017 Sep 12;8(1):524. doi: 10.1038/s41467-017-00650-0.
46. TRIM29 promotes DNA virus infections by inhibiting innate immune response. Junji Xing^#, Ao Zhang^#,  Hua Zhang, Jin Wang, Xian Chang Li*, Mu-Sheng Zeng*, Zhiqiang Zhang*. Nat Commun, 2017 Oct 16;8(1):945. doi: 10.1038/s41467-017-00101-w.  
47. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. Lin-Quan Tang^#, Chao-Feng Li^#, Jing Li^#, Wen-Hui Chen^#, Qiu-Yan Chen, Lian-Xiong Yuan, Xiao-Ping Lai, Yun He, Yun-Xiu-Xiu Xu, Dong-Peng Hu, Shi-Hua Wen, Yu-Tuan Peng, Lu Zhang, Shan-Shan Guo, Li-Ting Liu, Ling Guo, Yi-Shan Wu, Dong-Hua Luo, Pei-Yu Huang, Hao-Yuan Mo, Yan-Qun Xiang, Rui Sun, Ming-Yuan Chen, Yi-Jun Hua, Xing Lv, Lin Wang, Chong Zhao, Ka-Jia Cao, Chao-Nan Qian, Xiang Guo, Yi-Xin Zeng*, Hai-Qiang Mai*, Mu-Sheng Zeng*. J Natl Cancer Inst, 2015 Oct 14;108(1):djv291. doi: 10.1093/jnci/djv291.
48. In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. Chao Ni^#, Yuhui Chen^#, Musheng Zeng^#, Rongjuan Pei, Yong Du, Linquan Tang, Mengyi Wang, Yazhuo Hu, Hanyu Zhu, Meifang He, Xiawei Wei, Shan Wang, Xiangkai Ning, Manna Wang, Jufang Wang, Li Ma, Xinwen Chen, Qiang Sun, Hong Tang, Ying Wang*, Xiaoning Wang*. Cell Res, 2015 Jul;25(7):785-800. doi: 10.1038/cr.2015.50.  Epub 2015 Apr 28.
49. SPECT and near-infrared fluorescence imaging of breast cancer with a  neuropilin-1-targeting peptide. Guo-Kai Feng^#, Rong-Bin Liu^#, Meng-Qing Zhang^#, Xiao-Xuan Ye, Qian Zhong, Yun-Fei Xia, Man-Zhi Li, Jun Wang, Er-Wei Song, Xing Zhang*, Zhao-Zhong Wu*, Mu-Sheng Zeng*. J Control Release, 2014 Oct 28:192:236-42. doi: 10.1016/j.jconrel.2014.07.039.  Epub 2014 Jul 22.
50. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Li Yuan^#, Zhi-Hua Liu^#, Zhi-Rui Lin, Li-Hua Xu, Qian Zhong*, Mu-Sheng Zeng*. Cancer Biol Ther, 2014;15(12):1613-21. doi: 10.4161/15384047.2014.961874.
51. Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma. Jing-Ping Zhang^#, Hua Zhang^#, Hong-Bo Wang^#, Yan-Xian Li, Gui-Hong Liu, Shan Xing, Man-Zhi Li, Mu-Sheng Zeng. J Transl Med, 2014 Aug 7:12:222. doi: 10.1186/s12967-014-0222-1.  
52. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose  positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial  staging. Lin-Quan Tang^#, Qiu-Yan Chen^#, Wei Fan^#, Huai Liu^#, Lu Zhang, Ling Guo, Dong-Hua Luo, Pei-Yu Huang, Xu Zhang, Xiao-Ping Lin, Yun-Xian Mo, Li-Zhi Liu, Hao-Yuan Mo, Jian Li, Ru-Hai Zou, Yun Cao, Yan-Qun Xiang, Fang Qiu, Rui Sun, Ming-Yuan Chen, Yi-Jun Hua, Xing Lv, Lin Wang, Chong Zhao, Xiang Guo, Ka-Jia Cao, Chao-Nan Qian, Mu-Sheng Zeng, Hai-Qiang Mai. J Clin Oncol, 2013 Aug 10;31(23):2861-9. doi: 10.1200/JCO.2012.46.0816.  Epub 2013 Jul 15.
53. Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma. Hong-Bo Wang^#, Gui-Hong Liu^#, Hua Zhang, Shan Xing, Li-Juan Hu, Wei-Feng Zhao, Bo Xie, Man-Zhi Li, Bo-Hang Zeng, Yingqiu Li, Mu-Sheng Zeng. FEBS J, 2013 Jun;280(12):2929-44. doi: 10.1111/febs.12299.  Epub 2013 May 24.
54. Anti-tumour activity of longikaurin A (LK-A), a novel natural diterpenoid, in nasopharyngeal carcinoma. Qing-Feng Zou^#, Ji-Ke Du^#, Hua Zhang, Hong-Bo Wang, Ze-Dong Hu, Shu-Peng Chen, Yong Du, Man-Zhi Li, Dan Xie, Juan Zou, Han-Dong Sun, Jian-Xin Pu*, Mu-Sheng Zeng*. J Transl Med, 2013 Aug 28:11:200. doi: 10.1186/1479-5876-11-200.  
55. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. Feng-Hua Xu^#, Dan Xiong^#, Ya-Fei Xu^#, Su-Mei Cao, Wen-Qiong Xue, Hai-De Qin, Wen-Sheng Liu, Jing-Yan Cao, Ying Zhang, Qi-Sheng Feng, Li-Zhen Chen, Man-Zhi Li, Zhi-Wei Liu, Qing Liu, Ming-Huang Hong, Yin Yao Shugart, Yi-Xin Zeng, Mu-Sheng Zeng*, Wei-Hua Jia*. J Natl Cancer Inst, 2 2012 Sep 19;104(18):1396-410. doi: 10.1093/jnci/djs320.  Epub 2012 Sep 12.
56. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Bao-Hong Guo^#, Yan Feng^#, Rong Zhang, Li-Hua Xu, Man-Zhi Li, Hsiang-Fu Kung, Li-Bing Song, Mu-Sheng Zeng*. Mol Cancer, 2011 Jan 28;10(1):10. doi: 10.1186/1476-4598-10-10.
57. Low expression of Mel-18 predicts poor prognosis in patients with breast cancer. B-H Guo, X Zhang, H-Z Zhang, H-L Lin, Y Feng, J-Y Shao, W-L Huang, H-F Kung, M-S Zeng. Ann Oncol, 2010 Dec;21(12):2361-2369. doi: 10.1093/annonc/mdq241.
58. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. Qing-Li Kong^#, Li-Juan Hu^#, Jing-Yan Cao^#, Yi-Jun Huang, Li-Hua Xu, Yi Liang, Dan Xiong, Su Guan, Bao-Hong Guo, Hai-Qiang Mai, Qiu-Yan Chen, Xing Zhang, Man-Zhi Li, Jian-Yong Shao, Chao-Nan Qian, Yun-Fei Xia, Li-Bing Song, Yi-Xin Zeng, Mu-Sheng Zeng*. PLoS Pathog, 2010 Jun 3;6(6):e1000940. doi: 10.1371/journal.ppat.1000940.  
59. Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Jing-Yan Cao^#, Li Liu^#, Shu-Peng Chen, Xing Zhang, Yan-Jun Mi, Zhi-Gang Liu, Man-Zhi Li, Hua Zhang, Chao-Nan Qian, Jian-Yong Shao, Li-Wu Fu, Yun-Fei Xia*, Mu-Sheng Zeng*. Mol Cancer, 2010 Sep 9:9:237. doi: 10.1186/1476-4598-9-237.
60. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Wen-Ting Liao^#, Li-Bing Song^#, Hui-Zhong Zhang, Xing Zhang, Ling Zhang, Wan-Li Liu, Yan Feng, Bao-Hong Guo, Hai-Qiang Mai, Su-Mei Cao, Man-Zhi Li, Hai-De Qin, Yi-Xin Zeng, Mu-Sheng Zeng*. Clin Cancer Res, 2007 Jan 15;13(2 Pt 1):508-14. doi: 10.1158/1078-0432.CCR-06-1512.  
61. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Li-Bing Song, Mu-Sheng Zeng*, Wen-Ting Liao, Ling Zhang, Hao-Yuan Mo, Wan-Li Liu, Jian-Yong Shao, Qiu-Liang Wu, Man-Zhi Li, Yun-Fei Xia, Li-Wu Fu, Wen-Lin Huang, Goberdhan P Dimri, Vimla Band, Yi-Xin Zeng. Cancer Res, 2006 Jun 15;66(12):6225-32. doi: 10.1158/0008-5472.CAN-06-0094.
62. A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma. J Ri-Cheng Jiang^#, Hai-De Qin^#, Mu-Sheng Zeng^#, Wei Huang, Bing-Jian Feng, Feng Zhang, Han-Kui Chen, Wei-Hua Jia, Li-Zhen Chen, Qi-Sheng Feng, Ru-Hua Zhang, Xing-Juan Yu, Mei-Zhen Zheng, Yi-Xin Zeng. Cancer Res, 2 2006 Jan 15;66(2):693-700. doi: 10.1158/0008-5472.CAN-05-2166.
63. The human kallikrein 10 promoter contains a functional retinoid response element. Musheng Zeng, Ying Zhang, Ishfaq Bhat, David E Wazer, Hamid Band, Vimla Band. Biol Chem, 2006 Jun;387(6):741-7. doi: 10.1515/BC.2006.093.
64. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. Mu-Sheng Zeng, Da-Jiang Li, Qing-Lun Liu, Li-Bing Song, Man-Zhi Li, Ru-Hua Zhang, Xing-Juan Yu, Hui-Min Wang, Ingemar Ernberg, Yi-Xin Zeng. J Virol, 2005 Dec;79(24):15323-30. doi: 10.1128/JVI.79.24.15323-15330.2005.
65. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. Musheng Zeng, Ajay Kumar, Gaoyuan Meng, Qingshen Gao, Goberdhan Dimri, David Wazer, Hamid Band, Vimla Band. J Biol Chem, 2002 Nov 22;277(47):45611-8. doi: 10.1074/jbc.M208447200.  Epub 2002 Sep 15.

更新日期：2025年8月18日